MONDAY, Feb. 13 (HealthDay News) -- The cancer traduce in children with juvenile arthritis is four periods higher than in other children, a starting a~ study says.

This increased risk of cancer isn't indispensably linked to arthritis treatments, such as tumor necrosis factor (TNF) inhibitors, according to the study published online Feb. 13 in the periodical Arthritis & Rheumatism.

In the United States, TNF inhibitors effect a "black box" warning about the in posse cancer risk associated with the drugs.

In this study, the researchers analyzed 2000-2005 Medicaid facts from more than 7,800 children with juvenile arthritis and comparison groups of approximately 650,000 children with asthma and closely 322,000 children with attention-deficit hyperactivity disorder (ADHD).

The incidence censure of probable and highly probable cancers in children through juvenile arthritis was 4.4 general condition of affairs higher than in the other groups of children.

Juvenile idiopathic arthritis (JIA) in children is a inexact term covering different types of of long duration arthritis. Symptoms, similar to adult arthritis, include joint pain, swelling, tenderness and torpor.

"While our findings show children by [juvenile idiopathic arthritis] have a higher incidence of cancer compared to peers independently of JIA, the greater frequency of malignancy does not present itself to be necessarily associated with handling, including use of TNF inhibitors," concluded Dr. Timothy Beukelman, of the University of Alabama at Birmingham, in a diary news release.

"This highlights the captious importance of appropriate comparator groups then evaluating the safety of new medications. Further settlement of our findings with large-dish and long-term investigation of the combination between cancer and [juvenile arthritis] and its handling is needed," he added.

Most of the children with juvenile arthritis in the study were treated with injections of etanercept, a soluable TNF-receptor blocker. Other anti-TNF drugs that labor by different mechanisms may yield contrasted results, Dr. Karen Onel and Dr. Kenan Onel from the University of Chicago illustrious in an accompanying journal editorial.

But, "By focusing forward the possible cancer risk associated through the use of TNF inhibitors, the underlying cancer jeopardy associated with [juvenile arthritis] may wish been understated, and it is of high standing to make patients, families and physicians conscious of the possible late consequences of this ail," they added in the news excuse.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has in greater numbers about juvenile arthritis.

@yahoonews on Twitter, become a fan on Facebook